Last updated: 14 June 2024 at 4:55pm EST

Rachel Haurwitz Ph.D. Net Worth



Ms. Rachel Haurwitz Ph.D. biography

Rachel Haurwitz Ph.D. is the Co-Founder at Intellia Therapeutics Inc.



How old is Ms D?

Ms D is 34, she's been the Co-Founder of Intellia Therapeutics Inc since . There are 19 older and no younger executives at Intellia Therapeutics Inc. The oldest executive at Intellia Therapeutics Inc is Jesse Goodman, 68, who is the Independent Director.

What's Ms D's mailing address?

Rachel's mailing address filed with the SEC is C/O SEER, INC., 3800 BRIDGE PARKWAY, REDWOOD CITY, CA, 94065.

Insiders trading at Intellia Therapeutics Inc

Over the last 9 years, insiders at Intellia Therapeutics Inc have traded over $210,567,884 worth of Intellia Therapeutics Inc stock and bought 1,285,277 units worth $23,117,886 . The most active insiders traders include Carl L Gordon, Jean Francois Formela, and Bros. Advisors Lpbaker Feli.... On average, Intellia Therapeutics Inc executives and independent directors trade stock every 27 days with the average trade being worth of $1,357,638. The most recent stock trade was executed by Eliana Clark on 1 July 2024, trading 405 units of NTLA stock currently worth $9,287.



What does Intellia Therapeutics Inc do?

intellia therapeutic’s core mission is to develop curative medicines, utilizing the promise of the crispr/cas9 gene editing technology. the development of crispr/cas9 gene editing technology opens a new frontier in biomedical research and clinical intervention. adapted from a natural cellular process, crispr/cas9 permits the editing of any gene in any organism with unprecedented simplicity and flexibility. the incredible potential of this technology for treating human genetic disease inspired a group of life science veterans to create intellia therapeutics. intellia was founded in 2014 by caribou biosciences and atlas venture, along with a consortium of scientists who have helped define the space. intellia therapeutics holds exclusive access to a broad intellectual property portfolio covering the application of crispr/cas9 technology for human therapeutic use. intellia has built an experienced team of individuals to meet the challenges of bringing crispr/cas9 therapeutics to the



Intellia Therapeutics Inc executives and stock owners

Intellia Therapeutics Inc executives and other stock owners filed with the SEC include: